pharmaceuticals

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT…

5 days ago

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

January 04, 2026 16:00 ET  | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals,…

3 weeks ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

January 02, 2026 16:05 ET  | Source: Terns Pharmaceuticals, Inc. FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns…

3 weeks ago

Fermenta Ranked Among India’s Best Workplaces in Pharmaceuticals, Healthcare & Biotech by Great Place to Work

Recognition highlights Fermenta's strong people-first culture and high-trust workplaceRanking is determined through a structured evaluation combining confidential employee feedback with…

4 weeks ago

ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 20:00 ET  | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…

2 months ago

ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 01:00 ET  | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…

2 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

November 14, 2025 16:05 ET  | Source: Terns Pharmaceuticals, Inc. FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns…

2 months ago

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

–   Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of…

2 months ago

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek

CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…

3 months ago

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

October 24, 2025 11:39 ET  | Source: PMV Pharmaceuticals, Inc. Data presented today as an oral presentation at 2025 AACR-NCI-EORTC…

3 months ago